{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:48:59Z","timestamp":1787734139913,"version":"build-2784847793"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>This phase 2 trial investigated reinduction with carfilzomib, pomalidomide, and dexamethasone (KPd) and continuous pomalidomide\/dexamethasone in patients at first progression during lenalidomide maintenance. The second objective was to evaluate high-dose melphalan with autologous stem cell transplantation (HDM\/ASCT) at first progression. Patients were eligible who had progressive disease according to International Myeloma Working Group (IMWG) criteria. Treatment consisted of 8 cycles carfilzomib (20\/36\u2009mg\/m<jats:sup>2<\/jats:sup>), pomalidomide (4\u2009mg) and dexamethasone. Patients without prior transplant received HDM\/ASCT. Pomalidomide 4\u2009mg w\/o dexamethasone was given until progression. One hundred twelve patients were registered of whom 86 (77%) completed 8 cycles of KPd. Thirty-five (85%) eligible patients received HDM\/ASCT. The median time to discontinuation of pomalidomide w\/o dexamethasone was 17 months. Best response was 37% \u2265 complete response, 75% \u2265 very good partial response, 92% \u2265 partial response, respectively. At a follow-up of 40 months median PFS was 26 and 32 months for patients who received KPd plus HDM\/ASCT and 17 months for patients on KPd (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.37-1.00, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.051). PFS was better after longer duration of prior lenalidomide (HR 3.56, 95% CI 1.42-8.96, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.035). Median overall survival (OS) was 67 months. KPd-emerging grade 3 and 4 adverse events included hematologic (41%), cardiovascular (6%), respiratory (3%), infections (17%), and neuropathy (2%). KPd followed by continuous pomalidomide is an effective and safe triple drug regimen in second-line for patients previously exposed to bortezomib and\/or refractory to lenalidomide.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000786","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:28:52Z","timestamp":1664558932000},"page":"e786","source":"Crossref","is-referenced-by-count":25,"title":["Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma"],"prefix":"10.1002","volume":"6","author":[{"given":"Pieter","family":"Sonneveld","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam Cancer Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 degli Studi, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Troia","sequence":"additional","affiliation":[{"name":"Hematology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[{"name":"Hematology, University Hospital, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Croockewit","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Hematology Division and Hemato-Oncology Department, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, University of Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalung","family":"Wu","sequence":"additional","affiliation":[{"name":"Hematology, ZNA Stuivenberg, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"Droogendijk","sequence":"additional","affiliation":[{"name":"Hematology, Elisabeth Tweesteden Hospital, Tilburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Maastricht Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ostrava Poruba FNO, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Teresa Petrucci","sequence":"additional","affiliation":[{"name":"Department of Hematology, La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ypma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Haga Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Zojer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Wilhelminen Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, Utrecht University, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Italy"},{"name":"Division of Hematology, Citt\u00e0 della Salute e della Scienza, Universit\u00e0 di Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"R1-20231117","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"key":"R2-20231117","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"R3-20231117","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma.","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20231117","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"R5-20231117","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma.","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20231117","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"R7-20231117","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"R8-20231117","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study.","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"R9-20231117","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"R10-20231117","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20231117","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial.","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"R12-20231117","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"R13-20231117","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"R14-20231117","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"R15-20231117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"R16-20231117","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2015.125864","article-title":"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed\/refractory multiple myeloma.","volume":"100","author":"San Miguel","year":"2015","journal-title":"Haematologica"},{"key":"R17-20231117","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3324\/haematol.2019.217448","article-title":"Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.","volume":"105","author":"Mateos","year":"2020","journal-title":"Haematologica"},{"key":"R18-20231117","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"key":"R19-20231117","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2217\/fon-2019-0431","article-title":"Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA Phase III study design.","volume":"16","author":"Moreau","year":"2020","journal-title":"Future Oncol"},{"key":"R20-20231117","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"R21-20231117","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/annonc\/mdv325","article-title":"Carfilzomib and pomalidomide in patients with relapsed and\/or refractory multiple myeloma with baseline risk factors.","volume":"26","author":"Dimopoulos","year":"2015","journal-title":"Ann Oncol"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:06:52Z","timestamp":1702922812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000786","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}